skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 12,139  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: subject: Clinical Trials remove subject: Research & Development remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The Structure of Clinical Translation: Efficiency, Information, and Ethics
Material Type:
Article
Add to My Research

The Structure of Clinical Translation: Efficiency, Information, and Ethics

The Hastings Center report, 2015-03, Vol.45 (2), p.27-39 [Peer Reviewed Journal]

2015 The Hastings Center ;Copyright Blackwell Publishing Ltd. Mar-Apr 2015 ;ISSN: 0093-0334 ;EISSN: 1552-146X ;DOI: 10.1002/hast.433 ;PMID: 25628068 ;CODEN: HSCRAS

Full text available

2
Knowledge translation in health: how implementation science could contribute more
Material Type:
Article
Add to My Research

Knowledge translation in health: how implementation science could contribute more

BMC medicine, 2019-05, Vol.17 (1), p.88-88, Article 88 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1741-7015 ;EISSN: 1741-7015 ;DOI: 10.1186/s12916-019-1322-9 ;PMID: 31064388

Full text available

3
The COVID-19 Innovation System
Material Type:
Article
Add to My Research

The COVID-19 Innovation System

Health affairs (Millwood, Va.), 2021-03, Vol.40 (3), p.400-5 [Peer Reviewed Journal]

Copyright The People to People Health Foundation, Inc., Project HOPE Mar 2021 ;ISSN: 0278-2715 ;EISSN: 1544-5208 ;EISSN: 2694-233X ;DOI: 10.1377/hlthaff.2020.02097 ;PMID: 33539184

Full text available

4
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Material Type:
Article
Add to My Research

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

Nature reviews. Drug discovery, 2018-11, Vol.17 (12), p.854-855 [Peer Reviewed Journal]

Copyright Nature Publishing Group Dec 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.210

Full text available

5
A minimal common outcome measure set for COVID-19 clinical research
Material Type:
Article
Add to My Research

A minimal common outcome measure set for COVID-19 clinical research

The Lancet infectious diseases, 2020-08, Vol.20 (8), p.e192-e197 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(20)30483-7 ;PMID: 32539990

Full text available

6
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Material Type:
Article
Add to My Research

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

The Lancet (British edition), 2020-05, Vol.395 (10237), p.1613-1626 [Peer Reviewed Journal]

2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30932-6 ;PMID: 32580883

Full text available

7
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Material Type:
Article
Add to My Research

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

The Lancet infectious diseases, 2021-06, Vol.21 (6), p.803-812 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(20)30987-7 ;PMID: 33548194

Full text available

8
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Material Type:
Article
Add to My Research

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

The Lancet, 2020-05, Vol.395 (10236), p.1569-1578 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)31022-9 ;PMID: 32423584

Digital Resources/Online E-Resources

9
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Material Type:
Article
Add to My Research

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

The Lancet Infectious Diseases, 2021-02, Vol.21 (2), p.181-192 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2021. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(20)30843-4 ;PMID: 33217362

Digital Resources/Online E-Resources

10
Shigellosis
Material Type:
Article
Add to My Research

Shigellosis

The Lancet (British edition), 2018-02, Vol.391 (10122), p.801-812 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 24, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)33296-8 ;PMID: 29254859

Full text available

11
Computer-calculated compounds
Material Type:
Article
Add to My Research

Computer-calculated compounds

Nature (London), 2018-05, Vol.557 (7707), p.S55-S57 [Peer Reviewed Journal]

Copyright Nature Publishing Group May 31, 2018 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-018-05267-x

Full text available

12
Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups
Material Type:
Article
Add to My Research

Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups

BMC medicine, 2019-02, Vol.17 (1), p.47-47, Article 47 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;The Author(s). 2019 ;ISSN: 1741-7015 ;EISSN: 1741-7015 ;DOI: 10.1186/s12916-019-1283-z ;PMID: 30808345

Full text available

13
Across Time: A Chronological Progression of Clinical Trials in India
Material Type:
Article
Add to My Research

Across Time: A Chronological Progression of Clinical Trials in India

Curēus (Palo Alto, CA), 2024-03, Vol.16 (3), p.e56786-e56786 [Peer Reviewed Journal]

Copyright © 2024, Pathan et al. ;Copyright © 2024, Pathan et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Copyright © 2024, Pathan et al. 2024 Pathan et al. ;ISSN: 2168-8184 ;EISSN: 2168-8184 ;DOI: 10.7759/cureus.56786 ;PMID: 38650782

Full text available

14
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Material Type:
Article
Add to My Research

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine

Molecular therapy. Nucleic acids, 2017-09, Vol.8, p.132-143 [Peer Reviewed Journal]

2017 The Authors ;Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. ;2017. The Authors ;2017 The Authors 2017 ;ISSN: 2162-2531 ;EISSN: 2162-2531 ;DOI: 10.1016/j.omtn.2017.06.005 ;PMID: 28918016

Full text available

15
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Material Type:
Article
Add to My Research

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

The Lancet (British edition), 2016-02, Vol.387 (10019), p.679-690 [Peer Reviewed Journal]

Elsevier Ltd ;2016 Elsevier Ltd ;Copyright © 2016 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 13, 2016 ;2016. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(15)00803-X ;PMID: 26608256 ;CODEN: LANCAO

Full text available

16
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity
Material Type:
Article
Add to My Research

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity

The Lancet (British edition), 2018-09, Vol.392 (10150), p.880-890 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 8, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)31767-7 ;PMID: 30215383

Full text available

17
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
Material Type:
Article
Add to My Research

Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease

The New England journal of medicine, 2019-01, Vol.380 (4), p.315-324 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1809983 ;PMID: 30673543

Full text available

18
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Material Type:
Article
Add to My Research

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

The New England journal of medicine, 2019-11, Vol.381 (20), p.1929-1939 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1902626 ;PMID: 31722153

Full text available

19
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Material Type:
Article
Add to My Research

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

The Lancet (British edition), 2018-02, Vol.391 (10120), p.563-571 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 10, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)33106-9 ;PMID: 29217375

Full text available

20
The target landscape of clinical kinase drugs
Material Type:
Article
Add to My Research

The target landscape of clinical kinase drugs

Science (American Association for the Advancement of Science), 2017-12, Vol.358 (6367), p.1148-1148 [Peer Reviewed Journal]

Copyright © 2017 by the American Association for the Advancement of Science ;Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. ;Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works ;ISSN: 0036-8075 ;EISSN: 1095-9203 ;DOI: 10.1126/science.aan4368 ;PMID: 29191878

Digital Resources/Online E-Resources

Results 1 - 20 of 12,139  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1992  (10)
  2. 1992 To 1999  (77)
  3. 2000 To 2007  (495)
  4. 2008 To 2016  (2,418)
  5. After 2016  (9,140)
  6. More options open sub menu

Subject 

  1. R&d  (12,134)
  2. Medical Research  (11,875)
  3. Pharmaceutical Industry  (3,209)
  4. Patients  (3,096)
  5. Cancer Therapies  (3,036)
  6. Oncology  (2,812)
  7. Biotechnology Industry  (2,692)
  8. Tumors  (2,614)
  9. Collaboration  (2,610)
  10. Net Losses  (2,606)
  11. Cancer  (2,490)
  12. Coronaviruses  (2,157)
  13. Covid-19  (2,130)
  14. Drug Dosages  (1,807)
  15. Financial Performance  (1,789)
  16. Immunotherapy  (1,786)
  17. Stockholders  (1,574)
  18. Webcasting  (1,557)
  19. More options open sub menu

Language 

  1. English  (12,136)
  2. Japanese  (91)
  3. Urdu  (17)
  4. Chinese  (2)
  5. French  (1)
  6. German  (1)
  7. Spanish  (1)
  8. Norwegian  (1)
  9. More options open sub menu

Searching Remote Databases, Please Wait